drugset / Trial / NCT04484922
Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Neurodevelopmental disability is the most significant complication for survivors of infant surgery for congenital heart disease. In this study we sought to determine if intraoperative continuous infusion of dexmedetomidine are associated with neurodevelopmental outcomes at 12 months.
Timeline
- Start
- 2020-08-25
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 0.5 ug/kg | Other |